• 1
    Jemal A,Siegel R,Ward E,Murray T,Xu J,Smigal C,Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 10630.
  • 2
    Nelson WG,De Marzo AM,Isaacs WB. Prostate cancer. N Engl J Med 2003; 349: 36681.
  • 3
    Hessels D,Verhaegh GW,Schalken JA,Witjes JA. Applicability of biomarkers in the early diagnosis of prostate cancer. Expert Rev Mol Diagn 2004; 4: 51326.
  • 4
    Stamey TA,Caldwell M,McNeal JE,Nolley R,Hemenez M,Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004; 172: 1297301.
  • 5
    Lattouf JB,Saad F. Digital rectal exam following prostatectomy: is it still necessary with the use of PSA? Eur Urol 2003; 43: 3336.
  • 6
    Roberts SG,Blute ML,Bergstralh EJ,Slezak JM,Zincke H. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 2001; 76: 57681.
  • 7
    Bastian PJ,Yegnasubramanian S,Palapattu GS,Rogers CG,Lin X,De Marzo AM,Nelson WG. Molecular biomarker in prostate cancer: the role of CpG island hypermethylation. Eur Urol 2004; 46: 698708.
  • 8
    Gonzalgo ML,Isaacs WB. Molecular pathways to prostate cancer. JUrol 2003; 170: 244452.
  • 9
    Swindle PW,Kattan MW,Scardino PT. Markers and meaning of primary treatment failure. Urol Clin North Am 2003; 30: 377401.
  • 10
    Roupret M,Hupertan V,Yates DR,Catto JW,Rehman I,Meuth M,Ricci S,Lacave R,Cancel-Tassin G,de la Taille A,Rozet F,Cathelineau X, et al. Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin Cancer Res 2007; 13: 17205.
  • 11
    Rosenbaum E,Hoque MO,Cohen Y,Zahurak M,Eisenberger MA,Epstein JI,Partin AW,Sidransky D. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res 2005; 11: 83215.
  • 12
    Greene FL,Page DL. Genitourinary sites. Prostate. AJCC cancer staging manual, 6th edn. New York: Springer, 2002. 30917.
  • 13
    Enokida H,Shiina H,Urakami S,Igawa M,Ogishima T,Li LC,Kawahara M,Nakagawa M,Kane CJ,Carroll PR,Dahiya R. Multigene methylation analysis for detection and staging of prostate cancer. Clin Cancer Res 2005; 11: 65828.
  • 14
    Jeronimo C,Henrique R,Hoque MO,Mambo E,Ribeiro FR,Varzim G,Oliveira J,Teixeira MR,Lopes C,Sidransky D. A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 2004; 10: 84728.
  • 15
    Chu DC,Chuang CK,Fu JB,Huang HS,Tseng CP,Sun CF. The use of real-time quantitative polymerase chain reaction to detect hypermethylation of the CpG islands in the promoter region flanking the GSTP1 gene to diagnose prostate carcinoma. J Urol 2002; 167: 18548.
  • 16
    Maruyama R,Toyooka S,Toyooka KO,Virmani AK,Zochbauer-Muller S,Farinas AJ,Minna JD,McConnell J,Frenkel EP,Gazdar AF. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 2002; 8: 5149.
  • 17
    Bastian PJ,Palapattu GS,Lin X,Yegnasubramanian S,Mangold LA,Trock B,Eisenberger MA,Partin AW,Nelson WG. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res 2005; 11: 403743.
  • 18
    Jahr S,Hentze H,Englisch S,Hardt D,Fackelmayer FO,Hesch RD,Knippers R. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001; 61: 165965.